Free Trial

Verve Therapeutics (VERV) Earnings Date, Estimates & Call Transcripts

Verve Therapeutics logo
$4.55 0.00 (0.00%)
(As of 09:35 AM ET)

Verve Therapeutics Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 25Estimated
Actual EPS
(Nov. 5)
-$0.59 Beat By $0.11
Consensus EPS
(Nov. 5)
-$0.70

Verve Therapeutics posted Q3 2024 earnings on November 5, 2024, reporting an EPS of -$0.59, which beat the consensus estimate of -$0.70 by $0.11. Quarterly revenue rose 120.2% year-over-year to $6.87 million, above analysts' expectations of $2.75 million. With a trailing EPS of -$2.46, Verve Therapeutics' earnings are expected to decrease next year, from ($2.49) to ($2.91) per share.

VERV Upcoming Earnings

Verve Therapeutics' next earnings date is estimated for Tuesday, February 25, 2025, based off prior year's reporting schedules.

Get Verve Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verve Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

VERV Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

VERV Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Verve Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242-$0.79-$0.56-$0.68
Q2 20242-$0.63-$0.58-$0.61
Q3 20243-$0.72-$0.63-$0.67
Q4 20243-$0.72-$0.55-$0.62
FY 202410-$2.86-$2.32-$2.57
Q1 20252-$0.66-$0.60-$0.63
Q2 20252-$0.63-$0.63-$0.63
Q3 20252-$0.67-$0.65-$0.66
Q4 20252-$0.67-$0.66-$0.67
FY 20258($2.63)($2.54)($2.59)

Verve Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/25/2025
(Estimated)
------- 
11/5/2024Q3 2024-$0.70-$0.59+$0.11-$0.59$2.75M$6.87M
8/8/2024Q2 2024-$0.68-$0.59+$0.09-$0.59$2.40M$6.70M  
5/8/2024Q1 2024-$0.70-$0.59+$0.11-$0.59$2.11M$5.70M  
2/27/2024Q4 2023-$0.83-$0.69+$0.14-$0.69$3.95M$5.14M  
11/7/2023Q3 2023-$0.90-$0.72+$0.18-$0.72$0.96M$3.10M  
8/10/2023Q2 2023-$0.90-$0.87+$0.03-$0.87$0.67M$2.10M  
5/15/2023Q1 2023-$0.77-$0.84 -$0.07-$0.84$1.00M$1.40M  
3/2/2023Q4 2022-$0.76-$0.67+$0.09-$0.67$1.50M$1.01M  

Verve Therapeutics Earnings - Frequently Asked Questions

Verve Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates. Learn more on VERV's earnings history.

In the previous quarter, Verve Therapeutics (NASDAQ:VERV) reported ($0.59) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.70) by $0.11. Learn more on analysts' earnings estimate vs. VERV's actual earnings.

Verve Therapeutics (NASDAQ:VERV) has a recorded annual revenue of $11.76 million.

Verve Therapeutics (NASDAQ:VERV) has a recorded net income of -$200.07 million. VERV has generated -$2.46 earnings per share over the last four quarters.

Verve Therapeutics's earnings are expected to decrease from ($2.49) per share to ($2.91) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:VERV) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners